心房颤动患者经皮冠状动脉介入治疗术后三联抗栓治疗的研究进展  

Review on triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention

作　　者：刘文禹 俞晶晶[2] 陈传品[1] 阳国平[2] LIU Wen - yu YU Jing - jing CHEN Chuan - pin YANG Guo - ping(Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China Center of Clinical Pharmacology, The Third Xiangya Hospital of Central South University, Changsha 410013, China)

机构地区：[1]中南大学湘雅药学院,长沙410013 [2]中南大学湘雅三医院临床药理中心,长沙410013

出　　处：《中国临床药理学杂志》2017年第12期1161-1164,共4页The Chinese Journal of Clinical Pharmacology

基　　金：国家国际科技合作专项基金资助项目(2014DFA30900)

摘　　要：心房颤动患者中约有三分之一合并有冠心病,当这些患者进行经皮冠状动脉介入治疗(PCI)术后往往需要抗凝药物联合抗血小板的三联抗栓治疗,但是这种治疗方式出血风险较高。本文主要介绍了三联抗栓治疗的最新研究进展,为临床实践提供参考。A third of patients with atrial fibrillation（AF） complicated coronary heart disease（CHD）,most of them need to take triple antithrombotic therapy after undergoingpercutaneous coronary intervention.However, this treatment has a higher risk of bleeding. This review summarizes the recent researches on triple antithrombotic therapy,and hopes to provide a reference forclinical practice.

关 键 词：三联抗栓治疗 心房颤动 经皮冠状动脉介入 抗凝 

分 类 号：R973.2[医药卫生—药品]